[Protein-losing enteropathy in Rottweilers]

OBJECTIVES

To describe the signs, histopathological features, and treatment outcome of a not previously described protein-losing enteropathy (PLE) in Rottweiler dogs.

METHODS

A retrospective study involving 17 Rottweilers referred for PLE. Data on sex, age, presenting signs, histopathological diagnosis, and treatment outcome were collected. The canine inflammatory bowel disease activity index (CIBDAI) score was calculated, to quantify disease severity. Endoscopic intestinal biopsies were evaluated according to the guidelines of the World Small Animal Veterinary Association (WSAVA) gastrointestinal standardization group.

RESULTS

Presenting signs were watery diarrhoea and weight loss. In all dogs with PLE in this study, the abnormalities found were consistent with a form of inflammatory bowel disease. Some of the dogs had a secondary infection with Giardia or Cyniclomyces guttulatus. In 10 dogs (59%) the CIBDAI score was 9 or higher, indicative of severe disease. Histopathological findings revealed lymphoplasmacellular enteritis, with lymphangiectasia in 14 (82%) dogs and eosinophil infiltration in 10 (59%) dogs. Eleven (65%) dogs were euthanized or died because of the intestinal disease. Kaplan-Meier analysis revealed a median survival time of 5 months, with a 1-year survival rate of 47%. Seven (4%) dogs were disease-free after treatment with immunosuppressants and dietary measures, but some relapsed (median disease-free interval 21 months).

CLINICAL SIGNIFICANCE

In Rottweilers presenting with chronic diarrhoea and weight loss, clinicians should consider the presence of severe PLE, which has a poor prognosis.

Plasma 14 C-cholic acid clearance in healthy dogs and dogs with cholestasis or a congenital portosystemic shunt

The clearance profiles of intravenously injected tracer doses of radioactively labelled cholic acid were investigated in healthy dogs, dogs with a congenital portosystemic shunt and dogs with cholestasis. The rate constants and residual plasma activity were significantly different in the healthy and diseased dogs, but it was not possible to differentiate between the dogs with portosystemic shunting and cholestasis because the results were determined not only by factors involved in plasma bile acid clearance but also by the enterohepatic circulation.

Plasma concentrations of ACTH precursors correlate with pituitary size and resistance to dexamethasone in dogs with pituitary-dependent hyperadrenocorticism

This study was performed to determine whether in dogs with pituitary-dependent hyperadrenocorticism (PDH) excessive release of adrenocorticotrophic hormone (ACTH) is accompanied by secretion of ACTH precursor molecules. In addition, we investigated whether the plasma ACTH precursor concentrations were correlated with the size of the pituitary gland and with the degree of resistance to negative glucocorticoid feedback. In 72 dogs with PDH, the plasma ACTH precursor concentration was determined by calculating the difference between the results of a radioimmunoassay (RIA) in which besides ACTH, ACTH precursors were also measured and a highly specific immunoradiometric assay (IRMA) using a polyclonal antibody against ACTH. The degree of resistance to glucocorticoid feedback was established by determining the effect of dexamethasone administration (0.1mg/kg) on the urinary corticoid/creatinine ratio. The pituitary height/brain area (P/B) ratio, determined by computed tomography, was used as a measure for the size of the pituitary gland. The plasma ACTH precursors concentration ranged from 18 to 2233ng/L (median 93ng/L). In 38 dogs, the pituitary was enlarged and plasma ACTH precursors concentrations in these dogs (median 130ng/L, range 24-2233ng/L) were significantly (P<0.05) higher than those in the dogs without pituitary enlargement (median 72ng/L, range 18-481ng/L). In concordance, P/B ratios correlated significantly with plasma ACTH precursor concentrations (r=0.35, P<0.01). In addition, the P/B ratios were significantly correlated with the degree of dexamethasone resistance (r=0.42, P<0.001). Plasma ACTH precursor concentrations in the dexamethasone-resistant dogs (median 210ng/L, range 24-628ng/L) were significantly higher (P<0.01) than those in the dexamethasone-sensitive dogs (median 72ng/L, range 18-2233ng/L). Similarly, the degree of dexamethasone resistance was also significantly correlated with the plasma ACTH precursor concentrations (r=0.33, P<0.01). Dogs with an elevated plasma alpha-MSH concentration (n=14) had significantly (P<0.001) higher plasma ACTH precursor concentrations (median 271ng/L, range 86-2233ng/L) than dogs with non-elevated alpha-MSH (median 73ng/L, range 18-481ng/L). In addition, the plasma concentrations of alpha-MSH correlated significantly with both plasma ACTH precursor concentrations (r=0.53, P<0.001) and P/B ratios (r=0.26, P<0.05). In conclusion, in all dogs with PDH the ACTH concentrations determined by the RIA were higher than the concentrations measured by IRMA indicating the presence of circulating ACTH precursors. High plasma ACTH precursor concentrations were especially found in dexamethasone-resistant dogs with large corticotroph adenomas, some of them probably of PI origin. In the association of large corticotroph adenoma, dexamethasone resistance and high plasma concentrations of ACTH precursors, the decreased sensitivity of the corticotroph cells to glucocorticoid feedback may play a pivotal role.

Polycystic kidney and liver disease in cats

This paper reviews 27 cases of polycystic disease of the kidneys and/or liver in cats. The multiple cysts in the kidneys were rounded in all but one case, as described in adult polycystic kidney disease in humans. In 68% of the cats presented with polycystic kidneys, there were also cystic changes of the liver (uni- or multilocular cysts and/or congenital hepatic fibrosis (CHF)). In 1 cat polycystic changes of kidneys and liver were accompanied by cysts in the pancreas. In 5 cases there was severe pancreas fibrosis. Twenty-one of the 27 cats were Persian or Persian-crossbred.